Hosted on MSN23h
Psilocybin vs Lexapro; FDA's KarXT Decision Nears; Obesity and Schizophrenia
In a phase II trial of moderate-to-severe major depressive disorder, 6 weeks of intensive treatment with psilocybin or ...
The 'game-changing' treatment for schizophrenia
US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...
BioSpace3d
5 Schizophrenia Candidates Chasing BMS’ KarXT
As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...
BioSpace3d
Schizophrenia Space Anticipates First-in-Class FDA Approval for BMS’ KarXT
With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access ...
Medscape6d
Will 'Game Changer' Antipsychotic Live Up to the Hype?
The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...
Axios Vitals on MSN11h
FDA eyes first schizophrenia drug shift in decades
The Food and Drug Administration is slated to decide Thursday whether to approve the first new schizophrenia drug in at least ...
Becker's Hospital Review5h
FDA eyes 1st schizophrenia drug in decades: 5 things to know
The FDA is set to make a pivotal decision Sept. 26 about KarXT, a novel antipsychotic developed by Karuna Therapeutics. If approved, it would be the first drug with a unique mechanism for treating ...
Schizophrenia: the new drug set to tackle the ‘cancer of psychiatry’
But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness ...